Joshua Bauml, MD

R&D at J&J Innovative Medicine. Medical oncologist. Views mine. Tweets are not medical advice

[Joshua Bauml, MD @Jbauml]

FDA Priority Review has been granted for a potential new treatment option in recurrent or metastatic head & neck cancer. Building on progress in lung cancer, we're advancing innovation for patients with unmet needs. #Oncology https://t.co/oPQgoCzlYI

[Joshua Bauml, MD @Jbauml]

Treatment for #LungCancer touches every part of a person’s life. With a subcutaneous therapy available for #NSCLC, we’re continuing to rethink how care is delivered, with patients and care teams in mind. Read more: https://t.co/TUKoSDN01e

#JNJOncology #MyCompany

[Joshua Bauml, MD @Jbauml]

Head and neck cancer can be relentless. Even after treatment, many people see it return or continue to progress.

@JNJInnovMed's data at #ASCO26 focused on expanding options for these patients & supported our recent FDA filing. Learn more:

https://t.co/dqSGGde78x

[Joshua Bauml, MD @Jbauml]

This #HeadAndNeckCancerAwareness Month, @hncalliance held a Move-a-Thon & colleagues across @JNJInnovMed joined in.

I carried the spirit of moving on behalf of patients on a run while traveling in Asia.

Awareness, movement & solidarity matter everywhere & every month.

[Joshua Bauml, MD @Jbauml]

April is Head and Neck Cancer Awareness Month.

Head and neck cancer and how it’s treated can reshape how people speak, eat and live both during treatment and long after. That’s why awareness, education, and support across the care journey matter.

https://t.co/LlAj4Nf8je

[Joshua Bauml, MD @Jbauml]

At #MHNCS26, we’re sharing new data in head and neck cancer, an area where patients still need better options. I’m proud of the work our @JNJInnovMed teams are doing to advance new treatment approaches: https://t.co/KasnxPdNXc

#MyCompany

[Joshua Bauml, MD @Jbauml]

The U.S. FDA granted Breakthrough Therapy Designation to our sub-Q treatment for previously treated recurrent or metastatic head & neck cancer. It’s encouraging to see progress in a disease with limited options and historically poor outcomes: https://t.co/qHJGvr5ZmK

#MyCompany

[Joshua Bauml, MD @Jbauml]

Today, the U.S. FDA approved a monthly dosing schedule for our subcutaneous treatment for patients with EGFR-mutated NSCLC. Grateful to the teams at @JNJInnovMed who made this possible.

Learn more: https://t.co/x29PLTvFnI

#MyCompany #JNJOncology

[Joshua Bauml, MD @Jbauml]

With tens of thousands diagnosed daily, cancer impacts all of us—yet every journey is different. This #WorldCancerDay, we amplify the voices advancing care and hope: https://t.co/t852xzoX0I

#MyCompany #JNJOncology

[Joshua Bauml, MD @Jbauml]

Proud of the @JNJInnovMed team for advancing research in #ColorectalCancer and applying insights from our work in EGFR-driven cancers to help address this challenging disease. Learn more about our latest findings from #ASCOGI: https://t.co/Agn02LnGzd

#MyCompany

[Joshua Bauml, MD @Jbauml]

I was honored to join the @APIAHF on The Hot Pot podcast to discuss lung cancer—how we detect it, how we treat it, and the work we’re doing at @JNJInnovMed to support people throughout their care journey. #MyCompany

https://t.co/A6mgJWwaeE

[Joshua Bauml, MD @Jbauml]

Today’s approval of our sub-q treatment for EGFR-mutated #NSCLC raises the standard for what patients and their loved ones can expect from the treatment experience. Proud of the @JNJInnovMed team and what this means for patients. Learn more: https://t.co/F4YDuTtDao

#JNJOncology

[Joshua Bauml, MD @Jbauml]

Treating patients with lung cancer taught me that progress isn’t just measured in research, but in lives changed. At @JNJInnovMed, we’re advancing science to make that impact real for every patient.

Learn more: https://t.co/HkUxWkwNHG

#LungCancerAwarenessMonth #JNJOncology

[Joshua Bauml, MD @Jbauml]

Every advancement matters for patients with cancer. At #ESMO25, @JNJInnovMed shared new investigational data in recurrent or metastatic head and neck squamous cell carcinoma. Learn more: https://t.co/NaXDaycEfJ

[Joshua Bauml, MD @Jbauml]

Results published today in @NEJM underscore our determination @JNJInnovMed to push the boundaries of science and improve the treatment of EGFR-mutated non-small cell lung cancer.

https://t.co/4wMpGbwetD

#MyCompany #JNJOncology

[Joshua Bauml, MD @Jbauml]

Patients with #LungCancer deserve progress on both outcomes and treatment experience. At #WCLC25, @JNJInnovMed is sharing new data that brings us closer to that goal: https://t.co/CNpStIynTI

[Joshua Bauml, MD @Jbauml]

Lung cancer remains one of the toughest cancers to treat, but research is helping shift what’s possible. This #WorldLungCancerDay, I’m reflecting on how far science has come and how much more we still need to do for people with this disease: https://t.co/tKtkWsVScS
#JNJOncology

[Joshua Bauml, MD @Jbauml]

As #ASCO25 draws to a close I am leaving Chicago inspired by the amazing work being done by researchers to help patients with cancer around the world. This is truly one of the #BreathtakingMoments of working in oncology. Until next time ASCO!

[Jill Feldman @jillfeldman4]

Grateful to @JNJInnovation for the opportunity to be the lead author on #COCOON trial #PRO data at #ASCO25. It meant a lot to be a co-investigator and true partner and help shape the secondary endpoint to measure what matters to patients (#QOL matters)!
#LCSM

[Mark Wildgust (he/him) @MAWildgust]

Great to see @jillfeldman4 present results from #COCOON here at #ASCO25 on quality of life and prevention of skin reactions. At @JNJInnovMed we work collaboratively with all in the medical community to advance care for patients. #MyCompany